Aus$9m allocated for equipment in Australia's medical R&D programme:
This article was originally published in Clinica
Australia has allocated Aus$9m (US$6.6m) for new equipment as part of an Aus$102m medical research programme. In addition to the Aus$80m awarded last week to research into areas such as leukaemia, kidney disease, HIV/AIDS, cancer, maternal health, arthritis and melanoma, the government is providing Aus$2.5m to help commercialise the resulting products. Aus$10m will go to existing projects. So far, over 60 universities and research institutes have received funds or equipment upgrades. The government has earmarked almost Aus$500m for medical research in 2005.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.